- Home
- SCWO vs ENTA Comparison
SCWO vs ENTA Comparison
Compare SCWO & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCWO
- ENTA
- Stock Information
- Founded
- SCWO 2021
- ENTA 1995
- Country
- SCWO United States
- ENTA United States
- Employees
- SCWO N/A
- ENTA N/A
- Industry
- SCWO Environmental Services
- ENTA Biotechnology: Pharmaceutical Preparations
- Sector
- SCWO Utilities
- ENTA Health Care
- Exchange
- SCWO Nasdaq
- ENTA Nasdaq
- Market Cap
- SCWO 213.7M
- ENTA 245.4M
- IPO Year
- SCWO N/A
- ENTA 2013
- Fundamental
- Price
- SCWO $1.63
- ENTA $11.07
- Analyst Decision
- SCWO Strong Buy
- ENTA Buy
- Analyst Count
- SCWO 1
- ENTA 4
- Target Price
- SCWO $3.00
- ENTA $20.00
- AVG Volume (30 Days)
- SCWO 132.8K
- ENTA 113.5K
- Earning Date
- SCWO 11-15-2024
- ENTA 11-25-2024
- Dividend Yield
- SCWO N/A
- ENTA N/A
- EPS Growth
- SCWO N/A
- ENTA N/A
- EPS
- SCWO N/A
- ENTA N/A
- Revenue
- SCWO $244,730.00
- ENTA $71,960,000.00
- Revenue This Year
- SCWO N/A
- ENTA N/A
- Revenue Next Year
- SCWO $6,475.00
- ENTA $5.14
- P/E Ratio
- SCWO N/A
- ENTA N/A
- Revenue Growth
- SCWO N/A
- ENTA N/A
- 52 Week Low
- SCWO $0.83
- ENTA $8.08
- 52 Week High
- SCWO $2.09
- ENTA $17.80
- Technical
- Relative Strength Index (RSI)
- SCWO 52.83
- ENTA 42.54
- Support Level
- SCWO $1.36
- ENTA $10.84
- Resistance Level
- SCWO $1.65
- ENTA $11.83
- Average True Range (ATR)
- SCWO 0.13
- ENTA 0.57
- MACD
- SCWO -0.02
- ENTA -0.07
- Stochastic Oscillator
- SCWO 45.76
- ENTA 13.53
About SCWO 374Water Inc.
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The business activities of the company include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
About ENTA Enanta Pharmaceuticals Inc.
Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.